ライフサイエンスコーパス: HER2 gene

1 gesterone receptors and amplification of the HER2 gene.

2 -361 and MDA-453 cells, which do not exhibit HER2 gene amplification and are relatively resistant to

3 ression in HER2-positive breast cancers with HER2 gene amplification and HER2-low or HER2-negative br

4 used breast cancer cell lines to investigate HER2 gene amplification and modelled a range of differen

5 uggest that mammary tumors that contain both HER2 gene amplification and PIK3CA mutations should be t

6 uency and prognostic impact of heterogeneous HER2 gene amplification and polysomy 17 in patients with

7 ponents of breast cancers with heterogeneous HER2 gene amplification and to define the repertoire of

8 in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridiz

9 f these cases, heterogeneous distribution of HER2 gene amplification can be found, which creates clin

10 study was to determine whether the level of HER2 gene amplification determined by the HER2/CEP17 rat

11 HER2 gene amplification had been analyzed previously by

12 SH could be used for rapid identification of HER2 gene amplification in patient tissue.

13 on by immunohistochemistry (IHC) and lack of HER2 gene amplification measured by in situ hybridizatio

14 The level of HER2 gene amplification significantly predicts sensitivi

15 mutations occur primarily in the absence of HER2 gene amplification such that most HER2-mutant tumor

16 hat even driver genetic alterations, such as HER2 gene amplification, can be heterogeneously distribu

17 In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cel

18 stochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit from HER2 antibody-

19 e use of HER2-blocking agents to tumors with HER2 gene amplification, recent retrospective analyses s

20 extend to breast cancers that do not display HER2 gene amplification.

21 opulation in a process that does not require HER2 gene amplification.

22 reatment and relapse, despite persistence of HER2 gene amplification/overexpression.

23 tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventu

24 are currently approved for the treatment of HER2 gene-amplified breast cancers.

25 D1, and increased p27 protein levels in the HER2 gene-amplified BT-474 and SKBR-3 human breast cance

26 factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone recepto

27 ally indicated that MED1 is recruited to the HER2 gene and required for its expression.

28 meable peptide reduced the expression of the Her2 gene and specifically impaired the growth and viabi

29 the HER2 3' gene body, which we have termed HER2 gene body enhancer (HGE).

30 a therapeutic approach to incapacitating the Her2 gene by small organic molecules.

31 Here we show that the expression of the Her2 gene can be decreased by inhibiting the interaction

32 We analysed HER2 gene CNV used qPCR method in 87 sera collected from

33 HER2 gene CNV was also assessed in formalin-fixed paraff

34 Furthermore, we assessed the number of HER2 gene copies and HER2 expression in cancer cells usi

35 ve significantly more often a high number of HER2 gene copies in liquid biopsy (p = 0.04).

36 hybridization (FISH) result of more than six HER2 gene copies per nucleus or a FISH ratio (HER2 gene

37 g of 0 or 1+, a FISH result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than

38 Moreover, EGJC patients had higher number of HER2 gene copies than healthy donors (p = 0.0016).

39 se rate (ORR), overall survival, safety, and HER2 gene copy number (GCN >=20/<20) as a predictive fac

40 timal cutoff values for HER2/CEP17 ratio and HER2 gene copy number (GCN) for discriminating positive

41 No association was found between HER2 gene copy number and response (n = 39 patients) or

42 ation determined by the HER2/CEP17 ratio and HER2 gene copy number could significantly predict some b

43 We found that the HER2 gene copy number in liquid biopsy was higher in GC

44 of 6.11 (95% CI, 2.27 to 21.90) and a median HER2 gene copy number of 11.90 (95% CI, 3.30 to 43.80) w

45 ups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ h

46 HER2 gene copy numbers per cell were evaluated by fluore

47 EGFR and HER2 gene copy numbers were assessed by fluorescence in

48 Amplification of HER2 gene (ERBB2) and overexpression of HER2 protein on

49 In addition, HER2 gene expression was assessed using qPCR.

50 HER2 gene expression was prognostic and predictive in CA

51 that patients with a high copy number of the HER2 gene in the tumor tissue assessed by qPCR (but not

52 rkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation ty

53 The HER2 gene is amplified and overexpressed in approximatel

54 The HER2 gene is amplified in 20-30% of human breast cancers

55 Increased copy number of the HER2 gene is associated with gefitinib sensitivity in EG

56 and etiologically links amplification of the HER2 gene locus with human cancer pathogenesis.

57 ER2 gene copies per nucleus or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than

58 centromeric probe CEP17 is used to determine HER2 gene status in breast cancer.

59 number of 4 to 6, 41 (47.7%) of 86 had their HER2 gene status upgraded from nonamplified to amplified

60 ence genes might more accurately assess true HER2 gene status.

61 oncurrent RNAi-mediated silencing of FAS and HER2 genes synergistically stimulated apoptotic cell dea

62 Transcript levels of ESR1 and HER2 genes were available for 615 patients (12.1%) (coho

63 The HER2 gene, which encodes the growth factor receptor HER2

64 is of HER2-related diseases by detecting the HER2 gene with minimal consumption of samples and reagen